Publication: Determination of irinotecan, SN-38 and SN-38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients
2
Issued Date
2018-01-01
Resource Type
ISSN
10982825
08878013
08878013
Other identifier(s)
2-s2.0-85017550574
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Clinical Laboratory Analysis. Vol.32, No.1 (2018)
Suggested Citation
Chalirmporn Atasilp, Pichai Chansriwong, Ekapob Sirachainan, Thanyanan Reungwetwattana, Apichaya Puangpetch, Santirhat Prommas, Suwannee Sirilerttrakul, Budsaba Rerkarmnuaychoke, Sansanee Wongwaisayawan, Chonlaphat Sukasem Determination of irinotecan, SN-38 and SN-38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients. Journal of Clinical Laboratory Analysis. Vol.32, No.1 (2018). doi:10.1002/jcla.22217 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/45295
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Determination of irinotecan, SN-38 and SN-38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients
Other Contributor(s)
Abstract
© 2017 Wiley Periodicals, Inc. Background: Irinotecan (CPT-11) is chemotherapy used mainly in the metastatic colorectal cancer. The purpose of this study was to develop and validate the LC-MS/MS for the simultaneous determination of CPT-11, SN-38, and SN-38G. Methods: A 100 μL of plasma was prepared after protein precipitation and analyzed on a C18 column using 0.1% acetic acid in water and 0.1% acetic acid in acetonitrile as mobile phases. The mass spectrometer worked with multiple reaction monitoring (MRM) in positive scan mode. The standard curves were linear on a concentration range of 5-10 000 ng/mL for CPT-11, 5-1000 ng/mL for SN-38, and 8-1000 ng/mL for SN-38G. Results: In this assay, the intra and interday precision consisted of ≤9.11% and ≤11.29% for CPT-11, ≤8.70% and 8.31% for SN-38, and ≤9.90 and 9.64% for SN-38G. Conclusion: This method was successfully used to quantify CPT-11, SN-38, and SN-38G and applied to a pharmacokinetic study.